Kenvue stock steady as RBC reiterates Sector Perform amid Tylenol litigation

Kenvue Inc. (KVUE) reported a 'soft' Q2 2025, missing revenue and EPS forecasts, prompting analysts to lower price targets. This financial underperformance is compounded by significant legal and regulatory risks surrounding its key Tylenol brand, which contributes substantially to its $15.5 billion Self Care segment. The company faces ongoing litigation and potential negative publicity from a planned Health Secretary announcement regarding a possible link between Tylenol and autism, which could materially impact market perception and sales despite Kenvue's strong gross margins and dividend yield.

Analysis

Kenvue Inc. (KVUE) is confronting significant headwinds from both operational underperformance and escalating legal and regulatory pressures, causing its stock to trade near 52-week lows. The company's second-quarter 2025 results were notably weak, with adjusted EPS of $0.29 and revenue of $3.84 billion missing forecasts of $0.35 and $4.18 billion, respectively. This "soft" quarter, marked by a 4.2% decline in organic sales, prompted analysts at RBC, Jefferies, and Canaccord Genuity to lower their price targets, citing slower category growth and margin compression. Compounding these financial concerns is a material overhang from its Tylenol brand, a key component of the Self Care segment that generated $15.5 billion in FY2024 sales. A planned announcement from the U.S. Health Secretary linking acetaminophen use during pregnancy to autism, coupled with ongoing state and Canadian lawsuits despite the dismissal of federal cases, poses a substantial risk to consumer perception and future revenue. While the company maintains impressive gross profit margins of 58.15% and offers a 4.04% dividend yield, these fundamental strengths are currently overshadowed by the uncertainty surrounding its core brand and recent financial misses.

Key Decisions for Investors

• Investors should closely monitor upcoming announcements from the Department of Health and Human Services concerning acetaminophen, as any official report linking it to adverse health outcomes could serve as a significant negative catalyst for the stock.
• Given the stock is trading near 52-week lows, potential investors must weigh the attractive 4.04% dividend yield and high gross margins against the substantial legal risks and recent sharp decline in sales performance.
• It is crucial to watch for stabilization in Kenvue's top-line growth and margins in the coming quarters to determine if the Q2 2025 earnings miss was an anomaly or the beginning of a sustained negative trend.